Parallel import is based on the principle of free movement of goods within the EU-EEA (The European Economic Area).

Parallel importation of pharmaceuticals is original medicine being imported from an lowerpriced EU-EEA country, and then sold in another EU-EEA country with a higher price level. The medicine is sold on the same conditions as the original manufacturer's normal packaging. The medicine is being bought from approved wholesalers, and there is no difference between parallel imported medicine and the original medicine.

All imported pharmaceuticals have to be approved by the local medical authority – or the EMA (European Medicines Agency)

PharmAZet has comprehensive knowledge within this area and are able to provide support on:

• Complex services of parallel importer within EU
• Dossier compilation for PI application including RA support during registration process
• PV and RA support for parallel importers to follow current EU legislation
• Re-packaging sites
• Distribution network for purchase and sale of your PI products

Everybody's talking about market access. But far fewer appear able to define it. In the competitive world of pharmaceutical sales, developing a market access call strategy can pay dividends. But do you know what that means?

There are four basic elements. Essentially, market access is about:

• considering the implications your product may have on the wider healthcare market
• understanding the impact the changing healthcare market will have on your product
• preparing a positive healthcare environment which supports uptake of your product
• communicating the 'value' of your product to the range of customers who influence uptake